Department of Gastroenterology, Renai Branch, Taipei City Hospital, No. 10, Sec. 4, Renai Rd, Taipei 10629, Taiwan; Department of Psychology, National Chengchi University, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, National Taiwan University, 1 Chang-Te Street, Taipei 10002, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Research, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan.
Gastroenterol Clin North Am. 2020 Jun;49(2):201-214. doi: 10.1016/j.gtc.2020.01.010.
Enhancing host immunity by vaccination to prevent hepatitis B virus (HBV) infection remains the most important strategy for global control of hepatitis B. Currently, 187 countries have in place infant hepatitis B vaccination programs. Hepatitis B surface antigen prevalence has decreased to less than 1% in children after successful implementation of universal HBV vaccination in newborns. The incidence of primary liver cancer in children, adolescents, and young adults has drastically decreased to near zero in birth cohorts receiving hepatitis B vaccination. Elimination of chronic hepatitis B by 2030 is not a mission impossible.
通过接种疫苗增强宿主免疫力以预防乙型肝炎病毒（HBV）感染仍然是全球控制乙型肝炎的最重要策略。目前，187 个国家制定了婴儿乙型肝炎疫苗接种计划。在新生儿中成功实施乙型肝炎疫苗普遍接种后，儿童乙型肝炎表面抗原流行率已降至 1%以下。在接种乙型肝炎疫苗的出生队列中，儿童、青少年和青年人群原发性肝癌的发病率已急剧降至接近零。到 2030 年消除慢性乙型肝炎并非不可能完成的任务。
